The antibody MEM-258 recognizes an epitope on SCR4 (the membrane-proximal SCR) domain of CD46 (Membrane cofactor protein). CD46 is 56-66 kDa dimeric transmembrane protein expressed on T and B lymphocytes, platelets, monocytes, granulocytes, endothelial cells, epithelial cells and fibroblast; it is negative on erythrocytes.
The gene cluster of differentiation 46 (CD46) is localized in the regulators of complement activation gene cluster on human chromosome 1q32.2. The gene codes for a type 1 membrane bound protein called membrane cofactor protein (MCP). The encoded protein is characterized with an intracellular tail region with several variant structures such as, a single transmembrane α-helical region, a short region of unknown function (U), a collar STP-rich region and finally four extracellular complement control protein (CCP) domains involved in the cofactor activity. MCP is ubiquitously expressed.
Membrane cofactor protein (MCP) acts as a complement regulator and protects the cells from autologous complement-mediated damage. It plays a major role in inhibition of alternative pathway (AP), lectin pathway (LP) and classical pathway (CP). In addition, it also acts as a cellular receptor for certain pathogens such as the measles virus (Edmonston strain), human herpesvirus 6 and Neisseria gonorrhoeae. The encoded protein facilitates the fertilization of the human egg. Mutations in the CD46 gene has been observed in patients with preeclampsia and atypical hemolytic uremic syndrome (aHUS).
特徴および利点
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
物理的形状
PBS(15 mM アジ化ナトリウム、安定化剤として0.2%ハイグレード プロテアーゼフリーBSA含有)
免責事項
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Ad5-delta-24-RGD is currently the most clinically advanced recombinant adenovirus (rAd) for glioma therapy. We constructed a panel of fiber-modified rAds (Ad5RGD, Ad5/3, Ad5/35, Ad5/3RGD, and Ad5/35RGD, all harboring the delta-24 modification) and compared their infectivity, replication, reproduction, and cytolytic efficacy